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Abstract
New therapeutic agents are warranted in idiopathic membranous nephropathy. Synthetic
ACTH may be advantageous with reported remission rates up to 85% and few side effects.
We conducted a prospective open label cohort study from 2008 till 2010 (NCT00694863).
We prospectively selected patients with idiopathic membranous nephropathy and high risk
for progression (defined as βeta-2-microglobulin (β2m) excretion of >500 ng/min). For com-
parison, we selected matched historical controls treated with cyclophosphamide. The pro-
spectively selected patients received intramuscular injections of synthetic ACTH during 9
months (maximal dose 1 mg twice a week). The primary endpoints concerned the feasibility
and incidence of remissions as a primary event. Secondary endpoints included side effects
of treatment and the incidence of remissions and relapses at long-term follow-up. Twenty
patients (15 men) were included (age 54±14 years, serum creatinine 104 μmol/l [IQR 90–
113], urine protein:creatinine ratio 8.7 g/10 mmol creatinine [IQR 4.3–11.1]). Seventeen
patients (85%) completed treatment. 97% of injections were administered correctly. Cumu-
lative remission rate was 55% (complete remission in 4 patients, partial remission 7
patients). In a group of historical controls treated with cyclophosphamide and steroids, 19 of
20 patients (95%) developed a remission (complete remission in 13 patients, partial remis-
sion in 6 patients) (p<0.01). The main limitation of our study is its small size and the use of a
historical control group. We show that treatment with intramuscular injections of synthetic
ACTH is feasible. Our data suggest that synthetic ACTH is less effective than cyclophos-
phamide in inducing a remission in high risk patients with idiopathic membranous nephropa-
thy. The use of synthetic ACTH was also associated with many adverse events. Therefore,
we advise against synthetic ACTH as standard treatment in membranous nephropathy.
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Introduction
Idiopathic membranous nephropathy (iMN) is a common cause of adult nephrotic syndrome.
The recent discovery of anti-PLA2R antibodies in the majority of patients points to the autoim-
mune etiology of the disease. [1] Overall, approximately a third to up to half of patients develop
a spontaneous remission whereas the other part develops renal failure, often after a prolonged
period of stable but persistent proteinuria. [2–4]
Therapy in idiopathic membranous nephropathy remains debated. Two randomized con-
trolled trials evaluated the efficacy of treatment with alkylating agents in patients with iMN of
recent onset, with normal renal function and nephrotic range proteinuria. [5, 6] Immunosup-
pressive therapy increased remission rate and improved renal survival. However, in up to 50%
of untreated patients outcome was favorable. This means that up to 50% of patients were
unnecessarily exposed to treatment with toxic alkylating agents. Ideally, immunosuppressive
treatment should be restricted to patients with iMN at high risk for ESRD.
The most recent KDIGO guidelines recommend restricting initial therapy with 6 months of
cyclic steroids and cyclophosphamide (CP) to high-risk patients, defined as patients with per-
sisting nephrotic syndrome (>6 months), deteriorating kidney function during the first 6–12
months after diagnosis, or severe symptoms related to nephrotic syndrome. [7] Still, the serious
side effects of alkylating agents remain a concern. [8] Therefore, new non-toxic therapeutic
agents are warranted.
In 1999 Berg et al. described beneficial effects of synthetic ACTH in 14 patients with
nephrotic syndrome due to iMN. [9] Synthetic ACTH was administered to lower lipids in
patients with hyperlipoproteinemia, which is one of the features of nephrotic syndrome. Treat-
ment with synthetic ACTH led to the expected changes in serum lipid profile, but in addition
there was an unexpected 90% decrease of urinary albumin excretion. The proteinuria-lowering
effects of synthetic ACTH were confirmed in further studies of the same group, with prolonged
remission after a 2–11 months course of synthetic ACTH treatment in patients with several
proteinuric diseases (iMN, Minimal Change Disease, Mesangioproliferative glomerulonephri-
tis, Diabetic Nephropathy, Focal Segmental Sclerosis). [10] In a subsequent randomized con-
trolled trial 32 nephrotic patients with iMN were treated with either synthetic ACTH for 12
months or with the standard 6 months cyclical regimen with an alkylating agent (chlorambucil
or cyclophosphamide) and steroids. [11] Remission rates were similar in both groups (87 and
75% for ACTH and alkylating agents respectively) and treatment with ACTH only caused mild
side effects. Of note, patients in this RCT were not selected to have a high risk profile. The
promising results of the above-mentioned trials led to a renewed interest in ACTH as treat-
ment for iMN. [12–14]
Because the experience with synthetic ACTH in patients with iMN and high risk for renal
failure is limited, we conducted a prospective, open cohort study (NCT00694863) to assess the
safety and efficacy of synthetic ACTH in those patients.
Methods
A prospective, open label cohort study was conducted in our academic center from February
2008 till December 2010, with follow-up extended till June 2014 (S1, S2 and S3 checklists). This
study was registered at clinicaltrials.gov (NCT00694863). The study protocol met criteria
required by the Declaration of Helsinki and was approved by both the regional ethical board
(CMO regio Arnhem-Nijmegen) and the national authority (CCMO), all patients gave written
informed consent (S1 and S2 protocols). Our study was approved by the ethical committee
(CMO Arnhem-Nijmegen) on May 22nd 2008, and registered in the clinical trials registry (clin-
icaltrials.gov) at June 9th 2008. Registering the trial in a register before it was approved by the
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ethical board was not yet required and no common use in those days. The first participant
started with the study treatment on September 22nd 2008. Of note, the standardized urine mea-
surement of the first participant had taken place in February 2008 as part of routine patient
care. After approval of the study in May 2008, the patient was considered eligible for the study
based on the retrospective data from this measurement. Screening date therefore is considered
to be February 2008 for this patient. All other patients were screened and enrolled between
June 25th 2008 and December 29th 2010. There are no ongoing or related trials to this study.
Patients were recruited in our university hospital or one of the referring regional hospitals. Par-
ticipating patients were seen at our outpatient clinic for a standardized evaluation, as described
before. [15] During that evaluation eligibility criteria for participation in the ACTH study were
verified.
The study included adult patients (age 18–80 years) with biopsy proven MN. Eligible
patients had to have nephrotic syndrome (proteinuria 3.5 g/day and serum albumin 30 g/
l) despite conservative treatment, an eGFR> 60 ml/min/1.73m2, a high risk for ESRD, and a
(relative) contraindication to our standard treatment with cyclophosphamide and steroids.
High risk for ESRD was defined as an urinary βeta-2-microglobulin (β2m) excretion of>500
ng/min. [15] Relative contraindications to standard care were: young age (risk of infertility),
older age (> 60 years; more side effects of cyclophosphamide could be expected), previous
treatment with cyclophosphamide (to avoid high cumulative doses), and intolerance for cyclo-
phosphamide or high dose steroids. In case they had a (relative) contraindication for standard
treatment, later on, also patients with an eGFR> 40 ml/min/1.73m2 were included. We
excluded patients with secondary MN. [16] Other exclusion criteria were pregnancy, lactation
or inadequate use of contraceptives; evidence of underlying systemic diseases, active infection,
or active peptic ulcer disease; clinical evidence of renal vein thrombosis; severe asthma, known
hypersensitivities, and/or previous allergic reaction to synthetic ACTH.
Patients were treated with synthetic ACTH (tetracosatide hexaacetate, Synacthen Depot1,
Novartis, Switzerland) 1mg/ml suspension for intramuscular injection. ACTH was adminis-
tered in an increasing dose, starting with 1 mg every week and with a maximum of 1 mg twice
a week after 8 weeks (detailed treatment scheme adapted from the group of Berg, M. Arnadottir
personal communication, S1 Table). Maximum dose was continued for 18 weeks and tapered
afterwards, with a total treatment period of nine months and 59 injections. Since anaphylactic
reactions have been described with administration of ACTH and because this drug is not regis-
tered for routine use in our country, the ethical board required that all injections would be
administered in our hospital and patients had to be observed for 30 minutes after injection.
All patients were aggressively treated to decrease blood pressure (target value 130/80
mmHg), primarily by using angiotensin-converting enzyme inhibitors and/or angiotensin
receptor blockers. Statins were administered in case of hyperlipidemia. Anticoagulant drugs
were started when serum albumin levels dropped below 20 g/l (local current practice). All
patients were advised to use a moderately salt-restricted diet.
Follow-up time started from the moment of start of treatment. Since all injections were
administered in our hospital by one of the researchers, patients were frequently seen during
treatment. Adverse events were recorded at every visit. Clinical data and laboratory data were
collected at months 1, 2, 3, 5, 7 and 9 and every three months afterwards, with a final study
visit at 24 months. Patients were followed thereafter. Anti-PLA2R antibody measurement was
not available at the moment of inclusion in our study, which started in 2008. Subjects were
withdrawn from the study when renal function significantly deteriorated during treatment,
defined as an increase in serum creatinine of>25% over baseline value, or an increase to an
absolute value>135 μmol/l. In these cases standard immunosuppressive treatment, consisting
of cyclophosphamide and steroids, was initiated.
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The primary outcome parameters were the feasibility of intramuscular ACTH therapy
administered in the hospital twice a week and the incidence of remissions as a primary event
(either complete or partial). Feasibility was defined as the percentage of injections that was
administered correctly (at the indicated moment ± one day) during the complete treatment
period. Secondary endpoints included the number of patients that completed the study period
and the patient self-reported impact/burden on daily life of the treatment (on a scale of 1 to 10
(10 = highest level of satisfaction), not validated). Furthermore the change in proteinuria and
change in eGFR were assessed, as were side effects of treatment. At long-term follow-up the
incidence of remissions, relapses and use of additional treatment were assessed.
To evaluate the efficacy of ACTH, we compared the results obtained in the ACTH group
with data of matched historical controls. These historical controls were treated between 1998
and 2007 with cyclophosphamide (CP) (standard protocol 1.5 mg/kg/day for 12 months) and
steroids [17], and were matched for serum creatinine, proteinuria, age, gender and previous
immunosuppressive treatment.
Definitions and calculations
To correct for inappropriate 24-hour urine collections, amount of proteinuria was expressed as
protein-creatinine ratio (grams per 10 mmol of creatinine).
Complete remission (CR) was defined as a protein-creatinine ratio0.2 g/10 mmol creati-
nine with stable kidney function, and partial remission (PR) was defined as protein-creatinine
ratio<3.0 g/10 mmol creatinine with a reduction of>50% from baseline and stable kidney
function. Achieving remission includes both partial and complete remission. Nephrotic range
proteinuria was defined as a protein-creatinine ratio3.0 g/10 mmol creatinine. Relapse was
defined as nephrotic proteinuria and an increase of> 50% compared with the lowest value
during remission. We defined progression as 1) a rise in serum creatinine>50%, 2) a rise in
serum creatinine>25% and an absolute level135 μmol/l or 3) the need for immunosuppres-
sive therapy as judged by the treating physician. [18] An event was defined only after repeated
confirmatory measurements. We estimated GFR by applying the 4-variable MDRD equation.
[19]
Statistical analyses
Data are presented as number (percent), means (± SD) or medians (interquartile ranges [IQR])
when appropriate. T-test, Mann-Whitney U test and chi-squared test were used for compari-
sons between and within groups. Data were analysed on an intention to treat approach. The
cumulative probability of a clinical event was estimated according to Kaplan-Meier analysis
and evaluated using a log-rank test. All statistics were performed using IBM SPSS software, ver-
sion 20 (Chicago, IL). Differences were considered significant with p-value<0.05.
Patient inclusion. After inclusion of six patients an interim analysis was performed to
evaluate the feasibility of the study. This was required because not much was known about the
feasibility of intramuscular ACTH therapy twice a week in the year the study was started. After
approval the study was continued and in total 20 patients were included.
Results
From February 2008 till December 2010 20 patients were enrolled in the study. In total 108
patients were evaluated in our outpatient clinic during that period. Eventually 24 patients were
eligible for participating in the study; of whom 4 patients were not included (Fig 1). The base-
line characteristics of the 20 patients are shown in Table 1. In the ACTH treated group there
were 2 patients with diabetes mellitus, the time lag between biopsy showing no diabetic changes
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and initiation of ACTH was respectively 58 and 68 months. All patients in the ACTH group
received at least 4 months of a maximum dose of RAAS inhibition before study inclusion,
except for one patient that was only treated for 2.5 months with RAAS inhibition. Seventeen
patients (85%) completed treatment; one patient was withdrawn from the study after the first
injection because of progressive renal failure, in two other patients ACTH was stopped because
of side effects: in one patient after 14 injections because of severe dysregulation of her diabetes
mellitus and in one patient after 38 injections because of a delirium and infection. The percent-
age of injections that was administered correctly during the complete treatment period was
97%. The mean self-reported impact/burden of the treatment in the group on a scale of 1 to 10
was 7. An overview of the reported adverse events is listed in Table 2. Overall 19 patients (95%)
documented at least one or more adverse events. Dose reduction was necessary in 2 patients
(10%). Five patients needed hospitalization because of: hyperglycemia in known type I diabetes
mellitus (without ketoacidosis), hyperglycemia with severe dehydration, mood disorder and
dyspnea, and severe hypokalemia (n = 2). Mood disorders, oedema, myalgia/arthralgia,
Fig 1. Flowchart (algorithm) of patient inclusion. Legend: eGFR = estimated glomerular filtration rate (by
MDRD 4 equation), CI = contraindications, ACTH = synthetic ACTH, NS = nephrotic syndrome.
doi:10.1371/journal.pone.0142033.g001
Table 1. Baseline characteristics.
ACTH group (n = 20) Cyclophosphamide group (n = 20) P-value
Gender (male/female) 15:5 16:4 1.0
Age (years) 54 ± 15 50 ± 13 0.43
Diabetes mellitus 2 (10%) 1 (5%) 1.0
Serum creatinine (μmol/l) 104 [90–113] 97 [85–119] 0.81
Serum albumin (g/l) 22 ± 6.9 22 ± 5.5 0.96
eGFR (ml/min/1.73m²) 62 [52–76] 71 [53–76] 0.58
PCR (g/10 mmol Cr) 8.7 [4.3–11] 9.4 [6.7–12.2] 0.19
β2m excretion (ng/min) 2032 [685–3816] 3732 [1581–9673] 0.06
α1m excretion (μg/min) 55 [39–83] 72 [53–100] 0.12
Previous IS treatment 4 (20%)* 2 (10%)** 0.66
Interval Biopsy-T0 11 [3–56] 8 [6–13] 0.79
Follow-up (months) 46 ± 13 108 ± 45 <0.001
Values are expressed as number (percent), means ± SD and median [interquartile ranges]. ACTH = synthetic ACTH, eGFR = estimated glomerular
ﬁltration rate (by MDRD 4 equation), PCR = protein:creatinine ratio, β2m excretion = urinary beta2-microglobulin excretion, α1m excretion = urinary
alfa1-microglobulin excretion, min = minute, T0 = start of ACTH treatment.
* The interval between the end of previous treatment and start of the current treatment was respectively 20, 38, 80 and 162 months in the ACTH group.
** In the CP treated group this interval was 27 months in one patient and 257 months in the other patient.
doi:10.1371/journal.pone.0142033.t001
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sleeping disturbances, fever/ infection, flushing, erythema/local reaction and hyperpigmenta-
tion of the skin were among the most common reported adverse events.
Proteinuria decreased from 8.7 [IQR 4.3–11.1] at baseline to 2.0 g/10 mmol creatinine [IQR
0.8–4.5] at end of treatment, a reduction of 64% [IQR 41–91]. Meanwhile GFR increased from
62 [IQR 52–76] at baseline to 72 ml/min/1.73m2 [IQR 60–81] at end of therapy. The outcomes
after treatment with ACTH are depicted in Fig 2. Overall 11 patients (55%) developed a remis-
sion after treatment with ACTH; a complete remission in 4 patients and a partial remission in
7 patients (Table 3). Per-protocol analysis would increase the probability of response to 65%
(11 of the 17 patients who completed treatment). Time to remission was 5 months [IQR 5–12].
Of these 11 patients four persons (36%) developed a relapse during follow-up. Time to relapse
was 16 ±8 months. In total ten patients (50%) needed additional treatment because of renal
function deterioration (n = 3), persisting severe nephrotic syndrome (n = 5) and relapse
(n = 2). One of the patients with a persisting nephrotic syndrome was previously treated with
CP, none of the patients with renal deterioration was previously treated with another immuno-
suppressive agent. Of these 10 patients one patient was withdrawn from the study after the first
injection because of progressive renal failure, and the one patient who had to stop because of
severe dysregulation of her diabetes mellitus was treated with CP because of persisting
nephrotic syndrome. At the end of follow-up 14 patients (70%) were in remission, which was
complete in three of them, and partial in 11.
Table 2. Adverse events with ACTH treatment.
No. of events No. of patients (%)
Mood disorders/agitation 8 8 (40%)
Increasing oedema 12 12 (60%)
Myalgia/arthralgia 7 7 (35%)
Sleeping disturbances 10 10 (50%)
Fever/infection 9 8 (40%)
Flushing 7 7 (35%)
Hyperpigmentation skin 8 8 (40%)
Hypokalemia 7 3 (15%)
Erythema/local reaction 6 6 (30%)
Hypertension 5 5 (25%)
Weigth gain 6 6 (30%)
Acne 4 4 (20%)
Hyperglycemia 4 4 (20%)
Hair growth/hirsutism 4 4 (20%)
Cushingoid face 4 4 (20%)
Leukopenia 1 1 (5%)
Other 43 16 (80%)
Overall
No. of patients with 1 or more AE 19 (95%)
No. of patients needing dose decrease 2 (10%)
No. of SAE (hospitalizations) 5 (25%) 5 (25%)
AE = adverse events, SAE = serious adverse events.
doi:10.1371/journal.pone.0142033.t002
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Fig 2. Flowchart of treatment and events during follow-up in the ACTH group. Legend: ACTH = synthetic ACTH, CR = complete remission, PR = partial
remission, PNS = persisting nephrotic syndrome, RF = renal failure, 2nd treatment = alternative immunosuppressive treatment
doi:10.1371/journal.pone.0142033.g002
Table 3. Clinical outcomes ACTH group vs. Cyclophosphamide group.
ACTH group CP group p-value
Remission after ﬁrst therapy 11/20 (55%) 19/20 (95%) 0.01
Complete remission 4/11 13/19
Partial remission 7/11 6/19
Time to remission (m) 5 [5–12] 6 [3–8] 0.40
Relapse 4/11 (36%) 7/19 (37%)*
Time to relapse (m) 16 ± 8 86 ± 37 0.02
Follow-up (months) 46 ± 13 108 ± 45 <0.001
Remission at end of follow-up 14/20 (70%) 15/20 (75%) 1.00
Complete remission 3/14 6/15
Partial remission 11/14 9/15
Without additional treatment 7/14 (50%) 13/15 (87%) 0.05
Additional treatment 10/20 (50%) 4/20 (20%) 0.10
Relapse 2/10 3/4
Progressive disease 8/10 1/4
Values are expressed as number (percent), median [interquartile ranges] and mean ± SD.
ACTH = synthetic ACTH, CP = cyclophosphamide, m = months. Progressive disease = renal function
deterioration and persisting nephrotic syndrome.
*The relapse rate after 46 months is 5.3% (1/19 patients) in the CP group.
doi:10.1371/journal.pone.0142033.t003
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ACTH vs. Cyclophosphamide
For comparison we selected 20 historical controls treated with CP (Table 1); well matched for
baseline characteristics. In the CP group 18 patients (90%) completed treatment. Reasons for
withdrawal were severe leucopenia in one patient, for which CP was switched after one month
to azathioprine and prednisone during one year and in one patient treatment was discontinued
after 7 months for an unknown reason. Dose reduction because of side effects was necessary in
7 (35%) patients. This was not significantly different from the ACTH group. In the CP group
11 patients (55%) reported one or more adverse events; 7 patients developed bone marrow
depression, 5 patients suffered from an infection and 1 patient had a hyperglycemia.
Proteinuria decreased from 9.4 [IQR 6.7–12.2] at baseline to 0.6 g/10 mmol creatinine [IQR
0.3–1.0] at end of treatment, a reduction of 92% [IQR 85–97] with stable eGFR (71 [IQR 53–
76] at baseline to 71 ml/min/1.73 m² [IQR 55–77] at end of treatment). The decrease of pro-
teinuria was significantly higher during treatment with cyclophosphamide compared with
ACTH (92% versus 64%, p = 0.004). After treatment with CP, significantly more patients
developed a remission (Table 3). Both patients who had to discontinue treatment with CP
entered remission. Time to remission was not significantly different between the two groups.
The cumulative incidence of remission and time to remission are depicted in Fig 3.
Relapses occurred in four of the 11 (36%) patients in the ACTH group and in seven of the
19 (37%) patients in the CP group. Of note, the duration of follow-up was much longer in the
CP group. A log-rank test showed a shorter relapse free survival for patients in the ACTH
group (p = 0.02), depicted in Fig 4. In the CP group less patients needed additional immuno-
suppressive treatment during follow-up, although this was not significant (Table 3). Results
and conclusions were similar when comparing outcome in ACTH treated patients with out-
come in all CP treated patients (S2 Table).
Discussion
Our data show that treatment with intramuscular injections of synthetic ACTH twice a week
in an outpatient setting is feasible. The mean self-reported impact/burden of therapy was con-
siderably, with a score of 7 on a scale of 1 (very unsatisfied) to 10 (very satisfied). Although this
is not a validated measuring instrument, this reflects the substantial impact of the treatment
for patients, something that has not previously been mentioned in literature. Besides overall
response rate was moderate and we noted many adverse events.
In our study, all but one patient documented at least one adverse event. Five patients needed
hospitalization because of serious adverse events. Treatment was discontinued because of side
effects in two patients (10%). Thus far the documented adverse events in other studies were
considered as relatively mild. Still, in five out of 51 patients (10%) ACTH was withdrawn. [11,
13, 14]Thus, although most adverse events are mild, severe adverse events do occur during
treatment with (synthetic) ACTH and sometimes force discontinuation of treatment.
Our data suggest that treatment with synthetic ACTH is less effective than CP in inducing a
remission (55% vs. 95%) in high risk patients with iMN. At baseline urinary β2m excretion in
the CP treated group was higher than in the ACTH treated group. It is possible that CP treated
patients were therefore even more vulnerable for progression to kidney failure. Despite this dif-
ference however treatment with synthetic ACTH was less effective than CP in inducing a
remission and also more rapid relapses were noted in the ACTH treated group. At the end of
follow-up the rate of remission was equal in the ACTH and CP treated groups (70% and 75%
respectively), although patients in the ACTH group had needed more often additional therapy.
Moreover, no major differences between short time side effects were observed between the two
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Fig 3. Kaplan-Meier plot for cumulative incidence of remission. Legend: Number of patients at risk for a
remission at each time point are given below the figure. Log-rank test p = 0.005. ACTH = synthetic ACTH,
CP = cyclophosphamide.
doi:10.1371/journal.pone.0142033.g003
Fig 4. Kaplan-Meier plot for relapse free survival. Legend: Number of patients at each time point are given
below the figure. Log-rank test p = 0.020. ACTH = ACTH, CP = cyclophosphamide.
doi:10.1371/journal.pone.0142033.g004
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groups. Of note, adverse events were not recorded in the same way in the historical controls as
in the study population, the latter being actively questioned about side effects.
This is the first prospective study of synthetic ACTH in a cohort of patients with iMN at
high risk for end stage renal disease. Remission rates in other studies may have been inflated by
spontaneous remissions, which occur in up to half of unselected patients with iMN. [3, 10, 11,
20]
Indeed several authors have reported benefit of treatment with ACTH in patients with iMN
and a high risk profile.[12–14] However another formula of ACTH, i.e. H.P. Acthar1 gel was
used in these studies. Bomback et al. report on 11 patients with iMN, who previously had failed
a mean of 2.4 therapies.[12] Treatment with various doses of Acthar1 gel resulted in remission
of proteinuria in 9 patients, with complete remission in three of them. In a more recent pro-
spective study, 2 out of 5 patients with treatment resistant MN achieved a remission of protein-
uria after treatment with Acthar1 gel.[13] Hladunewich et al. treated twenty patients with
iMN (seven of them with partial response to other immunosuppressive regimens or significant
side effects during previous treatment) with 40 or 80 IU Acthar1 gel twice weekly during 12
weeks and in a subgroup (5 patients) for an additional 90 days after dose increase. [14] After 1
year of follow-up 2 patients achieved a complete remission (10%) and 10 patients achieved a
partial remission (50%). Definition of high risk in these above mentioned studies was different
from our criteria for high risk. This makes the comparison of our treated cohort with the
abovementioned patients difficult. We also cannot exclude differences in efficacy between syn-
thetic ACTH and Acthar1 gel, as there might be differences in active ingredients (see below)
and we don’t know if the doses of synthetic ACTH used and Acthar1 gel are comparable.
The particular strength of our study is that this is the first study in which ACTH was tested
in a homogeneous high risk group. Another strength is the long duration of follow up. The
main limitation of our study is its small size and the use of a historical control group. Therefore
the conclusions should be regarded with caution. Still, we feel that our data clearly suggest that
synthetic ACTH is less effective than cyclophosphamide in high risk patients with idiopathic
membranous nephropathy.
Anti-PLA2R measurement was not available at the inclusion period of our study. Hladune-
wich et al. previously showed that treatment with Acthar1 gel induced clearing of antibodies
prior to or in parallel with decrease in proteinuria in some, but not all anti-PLA2R positive
patients. As we previously showed, that anti-PLA2R antibodies rapidly disappeared after treat-
ment with cyclophosphamide in the majority of patients [21] it would have been interesting to
compare antibody response between our ACTH treated and cyclophosphamide treated groups.
It remains unknown how ACTHmight induce clinical remission in patients with iMN,
although many mechanisms of actions have been proposed. Synthetic ACTH is a long-chain
polypeptide composed of the first 24 of the 39 amino acids contained in the naturally occurring
ACTH (corticotrophin) molecule. The molecule can be cleaved, with the first 13 amino acids
forming α-melanocyte-stimulating hormone (α-MSH). (www.uniprot.org/uniprot/P01889)
Both peptides interact with melanocortin receptors (MCR, types 1–5 identified, with different
tissue distributions). It is unlikely that the antiproteinuric effect of ACTH is solely related to
increased release of cortisol and steroidogenesis via MCR2. [22] Other potential working
mechanisms of ACTH are: activation of MCR1 on podocytes [23], anti-inflammatory actions
in the kidney through MCR 2 interaction, direct MCR-mediated systemic immunomodulation
and anti-inflammatory effects on peripheral blood leukocytes (MCR 1, 3 and 5), kidney protec-
tion secondary to correction of dyslipidemia mediated by the MCR on hepatic cells (MCR 1, 5)
and renal protection via neurogenic anti-inflammatory effects mediated by MCR’s expressed in
the central nervous system (MCR 3, 4). [24] Acthar1 gel is obtained from processing porcine
pituitary glands. There is evidence that the synthetic analogues are different from natural
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occurring ACTH. For example, the β-cell tropic and insulinotropic effects of the endogeneous
hormone resides in the C-terminus of ACTH (fragment 18–39)[25], which is omitted from the
synthetic analogue but is retained in ACTH gel. Moreover, other active ingredients derived
from pro-opiomelanocortin (POMC), probably include additional melanocortin peptides such
as β- and γ-MSH. [24] It cannot be excluded that Acthar 1 gel has an additional mechanism of
action compared to synthetic ACTH. Direct comparisons between treatment with synthetic
ACTH and Acthar1 are needed.
In conclusion, treatment with intramuscular injections of synthetic ACTH is feasible. Our
data suggest that synthetic ACTH is less effective than CP in inducing a remission in high risk
patients with iMN. The use of synthetic ACTH was also associated with many adverse events.
Therefore, we advise against synthetic ACTH as standard treatment in membranous
nephropathy.
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